Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

O-2050

Δ8-THC sulfonamide analogue proposed as a neutral CB1 antagonist (Ki 2.5 nM); partial agonist on cAMP and in THC discrimination, antagonist in the vas deferens.

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₃H₃₁NO₄S

CID 16102146

Family
Synthetic CB receptor agonistResearch ligand or medicine
Molar mass
417.60 g/mol

Updated on

In plain terms

O-2050 was meant to be a laboratory tool able to block the CB1 receptor without doing anything else. A 2011 study showed that the picture is more mixed: a blocker in some tests on cells and tissues, it behaves like a partial cannabinoid in other tests and in mice. No study in humans was found.

Receptors and activity

Target network

CB1Partial agonistKi = 2.5 nM · rat[3H]CP55,940 displacement, rat cerebellum (2.5 ± 0.4 nM); cAMP (human CB1, CHO cells): partial agonist, Emax 37.4% against 74.4% for CP55,940 (EC50 40.4 nM); GTPγS: maximal stimulation of 11 ± 3%, KB 22 ± 8 nM; mouse vas deferens: pure antagonist, KB 1.0 ± 0.1 nM
  • Activates
  • Binds or modulates

The lower the cited value, the closer the target sits to O-2050: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of O-2050.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Cited values

  1. CB1Partial agonistKi = 2.5 nM · rat77 out of 100

    Wiley et al., Eur J Pharmacol 2011 (full text PMC3034309, table 1) (new tab) · [3H]CP55,940 displacement, rat cerebellum (2.5 ± 0.4 nM); cAMP (human CB1, CHO cells): partial agonist, Emax 37.4% against 74.4% for CP55,940 (EC50 40.4 nM); GTPγS: maximal stimulation of 11 ± 3%, KB 22 ± 8 nM; mouse vas deferens: pure antagonist, KB 1.0 ± 0.1 nM

  2. CB2Binding (function not established)Ki = 0.2 nM · mouse95 out of 100

    Wiley et al., Eur J Pharmacol 2011 (full text PMC3034309, table 1) (new tab) · mouse CB2 expressed in CHO cells (0.2 ± 0.1 nM); functional efficacy at CB2 not characterised in the study

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

O-2050 illustrates the difficulty of obtaining a truly neutral CB1 antagonist, rimonabant behaving as an inverse agonist at high concentrations. A sulfonamide analogue of Δ8-THC, it was widely used as a putative neutral antagonist, until the systematic evaluation by Wiley and colleagues (2011). Its binding is good (Ki 2.5 nM at rat CB1 and 0.2 nM at mouse CB2). In vitro, it antagonises agonists in the mouse vas deferens and on GTPγS binding, with no notable activity of its own; but on cAMP it acts as a partial agonist (Emax 37.4% versus 74.4% for CP55,940). In vivo in mice, it blocked neither Δ9-THC nor WIN 55,212-2, even given into the cerebral ventricles, it stimulated locomotor activity, decreased food intake and fully substituted for Δ9-THC in discrimination. The authors conclude that it cannot be classified as a neutral antagonist. These results are preclinical; no study in humans was found.

History

Source
An entirely synthetic compound with no natural occurrence. It is known as a pharmacology reagent (supplied by Organix in the study by Wiley et al. 2011); no clinical development was found in the sources consulted.

Origin

Laboratory synthesis

No biological pathway: O-2050 is a synthetic compound, a sulfonamide derivative of Δ8-THC, unrelated to the plant cannabinoid pathway.

Classification

Family, origin and source verification

Family

Synthetic CB receptor agonist › Research ligand or medicine

Class

classical

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

O-2050 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

IUPAC name
N-[6-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-3-yl]hex-4-ynyl]methanesulfonamide
Other names
O 2050 · O2050

Identifiers

Formula
C₂₃H₃₁NO₄S
InChIKey
DJTGGIYZQHHLGJ-RTBURBONSA-N
SMILES
CC1=CC[C@@H]2[C@@H](C1)C3=C(C=C(C=C3O)CC#CCCCNS(=O)(=O)C)OC2(C)C

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.